{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T14:48:39.704028",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 41,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "EU",
      "FR",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "overall survival (time from randomisation to death from any cause)",
        "overall survival (time between randomization and date of death from any cause)",
        "progression-free survival (PFS)",
        "progression-free survival (blinded, independent central review)",
        "progression-free survival (investigator-assessed)",
        "progression-free survival (RECIST)",
        "progression-free survival (independent, blinded review panel; RECIST 1.1)",
        "progression-free survival (measured by independent review committee; RECIST 1.1)",
        "event-free survival",
        "eventless survival",
        "prolonged survival",
        "progression after next line of therapy (PFS2)",
        "time to death (used for HRQoL measurement)",
        "mortality-related toxicity"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (RECIST 1.1)",
        "objective response rate (independent review committee; RECIST 1.1)",
        "overall response rate",
        "response rates",
        "disease control rate",
        "disease control rate (proportion of patients with complete, partial, or stable disease for at least 5 weeks)",
        "time to response (time from initiation of treatment to first complete or partial response)",
        "duration of response (DoR)",
        "duration of response (RECIST 1.1)",
        "treatment duration",
        "duration of treatment"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to next treatment (TTNT)",
        "time to next treatment"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events",
        "adverse events (CTCAE v5.0)",
        "adverse events (CTCAE v4.03)",
        "adverse events associated with intravenous treatments",
        "adverse events associated with cytotoxicity",
        "adverse events associated with dosing and frequency",
        "side effects",
        "serious undesirable effects",
        "serious adverse events",
        "serious adverse events (grade 3-4)",
        "serious side effects on the skin",
        "diarrhoea",
        "alanine aminotransferase increase",
        "aspartate aminotransferase increase",
        "neutropenia",
        "fatigue",
        "febrile neutropenia"
      ],
      "serious_events": [
        "serious undesirable effects",
        "serious adverse events",
        "serious adverse events (grade 3-4)",
        "serious side effects on the skin"
      ],
      "discontinuations": [
        "dropout rate"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-LC13",
        "BPI-SF",
        "FACT-G GP5",
        "PGI-C",
        "EQ-5D-5L",
        "visual analogue scale"
      ],
      "functional_status": [
        "Karnofsky performance status",
        "ECOG performance status",
        "physical functioning"
      ],
      "symptom_measures": [
        "symptomatology",
        "symptom control",
        "preservation of quality of life",
        "health status",
        "health-related quality of life",
        "health-related quality of life measured by time to death",
        "overall health status",
        "quality of life"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (cost per QALY achieved)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "utility decrement per cycle of treatment",
        "treatment-related disutility for intravenous administration"
      ],
      "resource_utilization": []
    },
    "other": {
      "exploratory_endpoints": [],
      "biomarkers": []
    }
  }
}